Pegargiminase
- Generic Name
- Pegargiminase
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1394129-74-8
- Unique Ingredient Identifier
- 0B7PYQ9YRT
- Background
Pegargiminase is an anticancer agent.
- Indication
Investigated for use/treatment in melanoma and hepatocellular carcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Glioblastoma Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Glioblastoma Pipeline Insight, 2024' report details 190+ companies developing 200+ therapies, including Enzastaurin, Marizomib, VT1021, and ONC201, with insights on mechanism of action, route of administration, and market dynamics.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath